Alpa Laboratories Ltd

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing challenges reflected in its financial and market performance.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a new 52-week low of Rs.55.1 today, marking a significant decline in its stock price amid ongoing underperformance relative to broader market indices and sector peers.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 02 March 2026, providing investors with the latest insights into its performance and outlook.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 19 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Alpa Laboratories Ltd., the Indore-based pharmaceutical formulations manufacturer, reported a sequential profit recovery in Q3 FY26 with net profit of ₹1.90 crores, marking a dramatic 1,627.27% quarter-on-quarter surge from the near-zero ₹0.11 crores in Q2 FY26. However, the year-on-year comparison reveals a concerning 78.65% decline from ₹8.90 crores in Q3 FY24, underscoring persistent operational challenges that have plagued the micro-cap pharmaceutical company throughout FY26.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 08 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 28 January 2026, providing investors with an up-to-date view of its performance and outlook.

Alpa Laboratories Ltd, a player in the Pharmaceuticals & Biotechnology sector, has touched a fresh 52-week low of Rs.63.76, marking a significant decline amid broader market pressures and company-specific performance issues.

Alpa Laboratories Ltd has declined to a fresh 52-week low of Rs.67.83, marking a significant downturn amid broader market fluctuations and company-specific performance issues. The stock’s recent slide reflects ongoing pressures in the Pharmaceuticals & Biotechnology sector, with the share price now trading well below all key moving averages.

Alpa Laboratories Ltd’s stock declined sharply to a fresh 52-week low of Rs.68.16 on 19 Jan 2026, marking a significant drop amid ongoing challenges in both its long-term and recent financial performance. The stock’s fall comes despite a broadly stable market environment, with the Sensex closing down 0.66% but still near its 52-week high.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. However, the analysis and financial metrics presented here reflect the stock's current position as of 05 January 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.73.65, marking a significant decline in its stock price amid a challenging market environment and subdued financial performance over the past year.

Alpa Laboratories Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 17 Nov 2025. While the rating change occurred on that date, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with an up-to-date view of the company’s performance and outlook.

Alpa Laboratories, a player in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low of Rs.75, marking a significant decline in its stock price amid broader market fluctuations and sectoral underperformance.

Alpa Laboratorie, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market evaluation reflecting ongoing challenges in its financial and technical outlook. Recent assessment changes highlight shifts across key performance parameters, signalling caution for investors amid subdued returns and operational difficulties.

Alpa Laboratories has reached a new 52-week low, with its share price touching Rs.76.25 today. This marks a significant level for the pharmaceutical and biotechnology company amid a broader market environment where the Sensex is trading slightly lower.